New Clinical Study Shows PleasureAir Technology Improves Orgasmic Difficulty in Perimenopausal, Menopausal and Post-Menopausal Women
By the year 2020, more than 50 million US women will go through menopause – and some will experience a decline in sexual function (JoAnn E. Manson, MD, DrPH). While a portion of those women will experience orgasmic difficulty, others may experience a decrease in sexual response – the ability to orgasm easily and experience powerful, toe-tingling sensations. To date, no FDA approved treatment exists for sexual arousal or orgasmic disorder in menopausal women nor does clinical research exist that tests the efficacy of an erotic toy like the Womanizer.
That’s why we conducted the study – to determine if our patented PleasureAir Technology can treat orgasmic difficulty in perimenopausal, menopausal and post-menopausal women. We’re pleased with the results which show our product is highly effective in helping menopausal women improve sexual function, sexual distress and overall quality of life.
The 4-week study was designed by Dr. Jennifer Berman, Urologist and Sexual Health Expert and administered by Brooke M. Faught, Clinical Director of Women’s Institute for Sexual Health (WISH), a division of Urology Associates.
It was conducted during October 2016 and included 22 menopausal women experiencing orgasmic difficulty with a mean age of 56. Women taking anti-depressants such as SSRIs (Selective Serotonin Reuptake Inhibitor), HRT (Hormone Replacement Therapy), and SERMs (Selective Estrogen Receptor Modulators) as well as oral hormonal contraceptives – medications known to negatively impact sexual function and orgasmic response in women, were included in the first-of-its-kind study.
Participants were asked to use the Womanizer at least twice weekly during the study and had to fill out validated questionnaires to determine if primary (change in sexual function and sexual distress) and secondary (overall satisfaction with sexual response, time to achieve orgasm and intensity of orgasm) endpoints improved. Validated questionnaires included the FSFI (Female Sexual Function Index), FDSD-R (Female Sexual Distress Scale) and SF-36 (Short Form Health Survey). Additionally, participants were asked to complete the FIEI (Female Intervention Efficacy Index) and a Global Assessment questionnaire at the conclusion of the study.